DENND3 Inhibitors
DENND3 inhibitors refer to a class of small molecules designed to modulate the activity of the DENND3 protein, primarily within a cellular context. DENND3, short for "Differentially Expressed in Normal and Neoplastic Cells Domain Containing 3," is a key regulatory protein involved in the cellular trafficking of membrane vesicles. Its primary function lies in the endocytic recycling pathway, where it acts as a guanine nucleotide exchange factor (GEF) for the small GTPase Rab12. This GEF activity enables DENND3 to facilitate the recycling of endocytosed proteins and membrane components back to the cell surface. The recycling process mediated by DENND3 plays a crucial role in maintaining the plasma membrane's integrity, cell adhesion, and receptor signaling, thereby influencing various cellular processes like cell migration, morphology, and adhesion.
Inhibitors targeting DENND3 typically aim to modulate its GEF activity, thus interfering with the recycling of specific membrane proteins or receptors. These inhibitors may function by binding to DENND3's active site or altering its conformation,blocking it from activating Rab12. By disrupting DENND3-mediated vesicle recycling, these inhibitors could impact various intracellular pathways and processes dependent on proper membrane trafficking. Consequently, DENND3 inhibitors have the to be valuable tools for understanding the intricate mechanisms of intracellular vesicle trafficking and may offer insights into the role of DENND3 in cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits tyrosine kinase activity of BCR-ABL, c-KIT, and PDGF receptors, disrupting cell signaling and inhibiting cell growth in leukemia and gastrointestinal stromal tumors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases in the RAF/MEK/ERK pathway and VEGFR, blocking angiogenesis and cell proliferation in various cancers, including renal cell carcinoma. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Specifically inhibits EGFR tyrosine kinase, preventing autophosphorylation and downstream signaling, leading to reduced cell proliferation in non-small cell lung cancer. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Acts as a BCR-ABL and Src family kinase inhibitor, suppressing aberrant signaling in chronic myeloid leukemia and some solid tumors. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits the proteasome, disrupting protein degradation and inducing apoptosis in multiple myeloma and mantle cell lymphoma cells. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Targets PARP enzymes involved in DNA repair, leading to synthetic lethality in BRCA-mutated cancer cells, particularly in ovarian and breast cancers. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Inhibits mTOR, a key kinase in the PI3K/AKT/mTOR pathway, blocking cell cycle progression and angiogenesis in various cancers, including renal cell carcinoma. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), inhibiting cell cycle progression and proliferation in hormone receptor-positive breast cancer. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Targets MEK1 and MEK2, key components of the RAF/MEK/ERK pathway, inhibiting cell proliferation in BRAF-mutated melanoma and other solid tumors. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Binds to BCL-2, inhibiting its interaction with pro-apoptotic proteins and promoting apoptosis in chronic lymphocytic leukemia (CLL) and other BCL-2-dependent cancers. | ||||||